Oncimmune logo

Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.

Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.

Contact Oncimmune via their website

News archive

01/11/2019   Oncimmune and Biodesix, Inc. start commercialisation of EarlyCDT® Lung in the US...more

23/09/2019   Oncimmune makes key appointments to further strengthen management teams...more

20/09/2019   Oncimmune announces €8.5m credit facility secured...more

09/08/2019   Positive trial results demonstrate potential of Oncimmune's Early CDT Lung test...more

03/08/2019   Oncimmune co-funded ECLS study recognised in top seven abstracts by IASLC...more

04/07/2019   Oncimmune signs commercialisation partnership in Russia...more

28/06/2018   Oncimmune Announes Commercialisation Agreement with Biodesix...more

04/06/2019   Oncimmune announces Positive Results for Early Cancer Detection Test...more

15/05/2019   Oncimmune Announces Regulatory Approval in Israel for EarlyCDT®—Lung...more

10/05/2019   Oncimmune Announces Multi-Centre Trial of EarlyCDT®—Lung in China...more

05/04/2019   Oncimmune Announces EarlyCDT®—Lung Distribution in Portugal...more

02/04/2019   Oncimmune appoints Dr Parag Mallick to Scientific Board...more
01/04/2019   Oncimmune Announces Registration of EarlyCDT^®‐Lung in Columbia...more
19/03/2019   Oncimmune Announces Acquisition of Protagen Diagnostics AG...more
13/02/2019   Oncimmune publishes half year results to Nov 2018...more
14/01/2019   Oncimmune to host Science Day at the Royal Institution...more

27/11/2018   Oncimmune's Early Lung Cancer Test Now Covered by MultiPlan...more
25/09/2018   Oncimmune Demonstrates Early Lung Cancer Detection Test at IASLC World Conference...more
13/09/2018   Oncimmune USA LLC Appoints Marco Casarin as General Manager...more
24/05/2018   Oncimmune Study Shows Cost-Effectiveness of EarlyCDT®-Lung Test...more
14/05/2018   Oncimmune Launches EarlyCDT®-Liver Test in the US...more
20/04/2018   Oncimmune joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code